PsoriazanProduct Information
CALCIPOTRIOL 0.005% / BETAMETHASONE DIPROPIONATE 0.064%

One gentle
Solution

For a Balanced Approach to
Plaque Psoriasis Management1

Topical OintmenteRX Code 74725
01 / MECHANISM OF ACTION

Complementary mechanisms.
One fixed-dose combination.

The dual mode of action of Calcipotriol and Betamethasone Dipropionate (Cal/BDP) simultaneously addresses multiple aspects of psoriasis in a complementary and synergistic manner.2

CALCIPOTRIOL

Vitamin D Receptor (VDR)

Regulation of genes controlling keratinocyte proliferation and differentiation.

  • ↓ Keratinocyte hyperproliferation
  • ↑ Epidermal differentiation
  • ↓ Dendritic-cell activation
  • ↓ Th1/Th17-driven inflammation
+
BETAMETHASONE DIPROPIONATE

Glucocorticoid Receptor (GR)

Modulation of inflammatory gene transcription.

  • ↓ Inflammatory signaling (TNF-α, IFN-γ, IL-17)
  • ↓ Inflammatory cells (CD4+ T cells, Th17)
  • ↓ Keratinocyte proliferation
  • ↑ Apoptosis of keratinocyte
  • Additive Suppression of the IL-23/IL-17 Inflammatory Axis
  • Complementary Immunomodulation
  • Improved Normalization of Epidermal Differentiation
  • Enhanced Microvascular Restoration
  • Reciprocal Mitigation of Treatment-Related Adverse Effects
02 / KEY BENEFITS

Four clinical attributes.
One treatment rationale.

01

Effective
Plaque Control3

Dual Targeting of the Key Pathogenic Drivers of PsoriasisAddresses both epidermal dysregulation and psoriatic inflammation

Synergistic Immunomodulation & Inflammatory SuppressionImprovement of erythema, scaling, pruritus, and plaque thickness

Improved Clinical EfficacyMeaningful reduction in PASI score and complete plaque control

02

Balanced
Safety Profile1,4

Reduced Corticosteroid BurdenOptimized corticosteroid exposure
Balanced risk-benefit profile

Optimized Local TolerabilityBetter cutaneous tolerability
Mild local adverse events

03

Simplified
Treatment Experience5

Once-Daily SimplicityA convenient once-daily regimen designed to reduce treatment complexity.

Fixed-Dose FormulationManufactured under GMP conditions, provides consistent quality and dose delivery.

04

Therapeutic
Ointment Vehicle6

Plaque HydrationOcclusive, emollient vehicle enhances hydration of hyperkeratotic plaques.

Scale SofteningPromotes softening of scales and facilitates penetration of active ingredients.

03 / CLINICAL PROFILES

For a Balanced Approach to
Plaque Psoriasis Management

Clinical Profiles Where an Ointment Vehicle May Be Particularly Appropriate6

Localized hyperkeratotic palmoplantar lesions
Localized hyperkeratotic
palmoplantar lesions
Recurrent flares requiring intermittent topical treatment
Recurrent flares requiring intermittent
topical treatment
Thick chronic plaques particularly on the trunk extremities elbows and knees
Thick, chronic plaques, particularly on the trunk,
extremities, elbows, and knees
04 / DOSAGE & ADMINISTRATION

Once-daily topical treatment.7

01

Application

Apply once daily to affected area(s) for up to 4 weeks; discontinue once control is achieved.

02

Maximum Weekly Dose

Adults: Max 100 g/week
Pediatric (12–17 years): Max 60 g/week

03

Precautions & Restrictions

Do not treat >30% Body Surface Area (BSA). Avoid occlusive dressings unless directed by a physician. Avoid use on face, groin, axillae, or areas with skin atrophy. For topical dermatologic use only.

Psoriazan topical ointment pack and tube
PRODUCT INFORMATION

Prescribing information
and references.

Download PDF ↗

References

  1. Gisondi P, Gracia-Cazaña T, Kurzen H, Galván J. J Clin Med. 2024;13(15):4484.
  2. Elmets CA, Korman NJ, Prater EF, et al. J Am Acad Dermatol. 2021;84:432–470.
  3. Kragballe K, Austad J, Barnes L, et al. Br J Dermatol. 2006;154(6):1155–1160.
  4. Van de Kerkhof PCM, Wasel N, Kragballe K, et al. Dermatology. 2005;210:294–299.
  5. Raychaudhuri SP, Raychaudhuri SK, Bagchi D, eds. Psoriasis and Psoriatic Arthritis. CRC Press; 2018.
  6. Rudnicka L, Olszewska M, Goldust M, et al. J Clin Med. 2021;10:5589.
  7. U.S. Food and Drug Administration. Taclonex® prescribing information. 2023.